Thallion Pharmaceuticals Inc.
TSX : TLN

Thallion Pharmaceuticals Inc.

July 11, 2012 18:05 ET

Thallion Announces 2012 Second Quarter Results

MONTRÉAL, QUÉBEC--(Marketwire - July 11, 2012) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced its operational and financial results for the three and six month periods ended May 31, 2012.

"We continue to execute on our focused Shigamabs® strategy. The results from the Phase II SHIGATEC trial confirmed Shigamabs® is safe and well tolerated. As the first trial in the targeted pediatric population, these results represent a critical step forward in the development of the product," said Dr. Allan Mandelzys, Chief Executive Officer of Thallion Pharmaceuticals. "The study has also provided us with important insights as we proceed with Shigamabs® development."

Operational Highlights

  • Announced positive top-line results, which met the primary endpoint of safety and tolerability, from the Phase II SHIGATEC trial evaluating the Company's Shigamabs® drug candidate as a treatment for Shiga toxin-producing E. coli (STEC) infection
  • Presented the top-line data from the Phase II SHIGATEC trial at VTEC 2012, the premier international E. coli symposium, demonstrating the safety and tolerability of Shigamabs® in a STEC-infected pediatric population
  • On July 10, 2012, the Toronto Stock Exchange ("TSX") notified the Company that it is reviewing the securities of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process.

Financial Highlights

Collaboration and licensing revenues for the three month and six month periods ended May 31, 2012, were $532,036 and $1,148,593 respectively, compared to $1,021,034 and $1,854,916 the three month and six month periods ended May 31, 2011. The decrease in revenues is primarily due to a decline in research and development expenses in the first half of 2012 compared to the first half of 2011, explained below, resulting in an approximate $200,000 and $350,000 reduction in recognized revenues, respectively. In addition, the Company had revised its estimate for clinical and manufacturing costs necessary to complete both the Phase II and Phase III SHIGATEC studies in the fourth quarter of 2011. This revised estimate directly impacts the percentage of completion calculation used to recognize revenues, resulting in lower revenue recognition in the first half of 2012 compared to the first half of 2011 at the same expenditure level.

Research and development (R&D) expenses before tax credits for the three month and six month periods ended May 31, 2012 were $895,470 and $1,924,033, respectively. This represents an 18% decrease in cost from $1,086,683 in the three month period ended May 31, 2011, and a 14% decrease in cost from $2,248,859 in the six month period ended May 31, 2011. The decrease in R&D expense was the result of reduced clinical trial expenditures of approximately $220,000 and $460,000 in the three months and six months ended May 31, 2012, respectively, due primarily to fewer patients being screened/recruited during the first half of 2012 than during the first half of 2011. These reductions in expenses were partially offset by respective increases of $69,000 and $114,000 related to completion of the core portion of the Phase II SHIGATEC trial.

General and administrative (G&A) expenses for the three month and six month periods ended May 31, 2012 were $626,731 and $1,239,859, respectively. G&A expenses were stable when compared with $653,628 and $1,260,902 in the three months and six months ended May 31, 2011, respectively.

The Company recorded a net loss of $723,971 or $0.02 per share in the three month period ended May 31, 201 2, compared with $781,648 or $0.02 per share in the corresponding period in 2011. For the six month period ended May 31, 2012, the Company recorded a net loss of $1,559,225 or $0.05 per share, compared to $1,791,458 or $0.06 per share for the same period last year. The decrease in net loss is primarily due to the reduction in R&D expenses as well as higher foreign exchange gains recognized as a result of changes in the fair value of foreign exchange forward contracts. These gains were partially offset by lower collaboration and licensing revenues.

As at May 31, 2012, the Company's unrestricted cash position amounted to $6,630,885, which consists of cash and short-term investments. The Company's liquidity availability amounted to $7,065,170 compared with $8,533,803 on November 30, 2011. The decrease in liquidity is primarily due to the reduction of trade and other payables in addition to cash expenses related to operations for the six month period ended May 31, 2012, offset by Shigamabs® development funding received from LFB. Furthermore, the Company's working capital amounted to $5,728,068 as at May 31, 2012, compared to $6,337,692 as at November 30, 2011, a decrease of $609,624 due primarily to activities related to the Company's first half of 2012 operations.

As of July 10, 2012, the Company had 32,194,566 common shares outstanding and a total of 3,676,450 stock options, following the issuance of 908,000 stock options on March 19, 2012.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product being evaluated in a Phase II clinical trial for the treatment of Shiga toxin producing E. coli bacterial infections. Additional information about the Company can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the satisfaction of conditions provided in the development and commercialization agreement with LFB, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Financial results included below:

THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Financial Position
(unaudited)
May 31,
2012
November 30,
2011
Assets
Current assets:
Cash $ 3,326,125 $ 5,005,687
Short-term investments 3,304,760 3,284,428
Foreign exchange forward contracts 225,676 103,445
Sales tax receivable and other assets 10,887 10,270
Tax credits receivable 434,285 243,688
Deposits and prepaid expenses 207,129 233,774
7,508,862 8,881,292
Restricted cash 1,000,000 1,000,000
Property and equipment 36,594 42,269
1,036,594 1,042,269
$ 8,545,456 $ 9,923,561
Liabilities and Equity (Deficiency)
Current liabilities:
Trade and other payables $ 1,503,032 $ 2,210,613
Provisions 277,762 332,986
1,780,794 2,543,599
Deferred revenues 7,919,430 7,001,794
Equity (Deficiency):
Share capital 115,512,823 115,512,823
Warrants 1,375,000 1,375,000
Contributed surplus 20,336,750 20,310,461
Deficit (138,379,341 ) (136,820,116 )
Equity (deficiency) attributable to equity holders of the Company (1,154,768 ) 378,168
$ 8,545,456 $ 9,923,561
THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(unaudited)
Three-month
periods ended
May 31
Six-month
periods ended
May 31
2012 2011 2012 2011
Revenues
Collaboration and licensing revenues $ 532,036 $ 1,021,034 $ 1,148,593 $ 1,854,916
Expenses (income)
Research and development 895,470 1,086,683 1,924,033 2,248,859
Tax credits (95,715 ) (98,575 ) (190,597 ) (190,170 )
799,755 988,108 1,733,436 2,058,689
General and administrative 626,731 653,628 1,239,859 1,260,902
Finance (income) costs
Interest income (15,597 ) (12,704 ) (31,739 ) (27,925 )
Foreign exchange gain (54,344 ) (55,917 ) (5,234 ) (6,516 )
Changes in fair value of foreign exchange forward contracts (100,538 ) 229,567 (228,504 ) 361,224
1,256,007 1,802,682 2,707,818 3,646,374
Net loss and comprehensive loss attributable to equity holders of the Company $ (723,971 ) $ (781,648 ) $ (1,559,225 ) $ (1,791,458 )
Net basic and diluted loss per share $ (0.02 ) $ (0.02 ) $ (0.05 ) $ (0.06 )
Weighted average number of outstanding shares 32,194,566 32,194,566 32,194,566 32,194,566
THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Changes in Equity (Deficiency)
(unaudited)
Number
of
common
shares
outstanding
Share
capital
Number
of
warrants
outstanding
Warrants Contributed
surplus
Deficit Equity
(deficiency)
attributable
to equity
holders
of the
Company
Balance, November 30, 2011 32,194,566 $ 115,512,823 530,000 $ 1,375,000 $ 20,310,461 $ (136,820,116 ) $ 378,168
Net loss and total comprehensive loss - - - - - (1,559,225 ) (1,559,225 )
Transactions with owners recorded directly in equity:
Stock-based compensation - - - - 26,289 - 26,289
Balance, May 31, 2012 32,194,566 115,512,823 530,000 1,375,000 20,336,750 (138,379,341 ) $ (1,154,768 )
Number
of
common
shares
outstanding
Share
capital
Number
of
warrants
outstanding
Warrants Contributed
surplus
Deficit Equity
(Deficiency)
attributable
to equity
holders
of the
Company
Balance, December 1, 2010 32,194,566 $ 115,512,823 530,000 $ 1,375,000 $ 20,230,421 $ (132,787,624 ) $ 4,330,620
Net loss and total comprehensive loss - - - - - (1,791,458 ) (1,791,458 )
Transactions with owners recorded directly in equity :
Stock-based compensation - - - - 45,562 - 45,562
Balance, May 31, 2011 32,194,566 115,512,823 530,000 1,375,000 20,275,983 (134,579,082 ) 2,584,724
THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)
Six-month periods ended
May 31
2012 2011
Cash flows used in operating activities:
Net loss $ (1,559,225 ) $ (1,791,458 )
Adjustments for:
Depreciation 6,678 10,129
Finance income - interest income (31,739 ) (27,925 )
Interest received 31,898 42,592
Gain on disposal of property and equipment (25,331 ) (22,897 )
Effect of exchange rate fluctuations on cash held 20,517 64,347
Decrease (increase) in fair value of open foreign exchange forward contracts (122,231 ) 298,085
Stock-based compensation 26,289 45,562
(1,653,144 ) (1,381,565 )
Changes in operating assets and liabilities:
Sales tax receivable and other assets (776 ) 26,532
Tax credits receivable (190,597 ) (190,170 )
Receivable from Premium Brands Holdings Corporation - 292,249
Deposits and prepaid expenses 26,645 82,167
Trade and other payables (707,581 ) (1,864,652 )
Provisions (55,224 ) (265,711 )
Deferred revenues 917,636 997,201
(9,897 ) (922,384 )
(1,663,041 ) (2,303,949 )
Cash flows from investing activities:
Acquisition of short-term investments (1,020,332 ) (2,030,252 )
Proceeds from disposal/maturity of short-term investments 1,000,000 2,791,962
Additions to property and equipment (1,003 ) (6,555 )
Proceeds from disposal of property and equipment 25,331 22,897
3,996 778,052
Net decrease in cash (1,659,045 ) (1,525,897 )
Cash, beginning of period 5,005,687 6,228,340
Effect of exchange rate fluctuations on cash held (20,517 ) (64,347 )
Cash, end of period $ 3,326,125 $ 4,638,096

Contact Information